Stock Events

Stock Events

Herantis Pharma OYJ 

€1.1860
6
+€0.01+0.51% 16:29 Today

Statistics

Day High
1.206
Day Low
1.154
52W High
2.87
52W Low
1.118
Volume
16,432
Avg. Volume
30,563
Mkt Cap
31.43M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 20Expected
Q2 2023
Q4 2023
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.14
-0.11
-0.09
-0.06
Expected EPS
-0.058634274048
Actual EPS
-0.087951411072

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-6.62MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HRTIS.HE. It's not an investment recommendation.
Telia Company AB
3
TELIA1.HE
Neste OYJ
3
NESTE.HE
Nokia
2
NOKIA.HE
Nordea Bank Abp
2
NDA-FI.HE

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap37.49B
Biogen Inc. focuses on neurodegenerative diseases, directly competing with Herantis Pharma's CNS drug development.
Novartis
NVS
Mkt Cap303.67B
Novartis AG has a strong portfolio in neuroscience and advanced therapies, overlapping with Herantis Pharma's focus areas.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG invests heavily in neurology and rare diseases, areas where Herantis Pharma is also active.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has a diversified portfolio that includes treatments for neurological conditions, competing with Herantis Pharma's products.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is involved in neurodegenerative diseases research, making it a competitor in the same field as Herantis Pharma.
Lilly(Eli) &
LLY
Mkt Cap1.26T
Eli Lilly and Company has a strong emphasis on Alzheimer's disease, directly competing with some of Herantis Pharma's research areas.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie Inc. has expanded its neuroscience portfolio, including Parkinson's disease treatments, competing with Herantis Pharma.
AMGEN
AMGN
Mkt Cap251.94B
Amgen Inc. has been expanding its focus on neurodegenerative diseases, making it a competitor to Herantis Pharma.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap49.09B
Teva Pharmaceutical Industries Limited offers generic and specialty medicines, including for CNS disorders, competing with Herantis Pharma.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca PLC has a growing focus on neurology and bio-pharmaceuticals, areas of interest for Herantis Pharma.

About

Herantis Pharma Oyj, a biotechnology company founded in Espoo, Finland, in 2008, is dedicated to developing innovative, disease-modifying CDNF-based treatments for Parkinson's disease (PD). Its pipeline features two key assets: HER-096, an advanced small, synthetic chemical peptidomimetic (a modified version of the active CDNF parent molecule) which is in preclinical stages as an xCDNF candidate for Parkinson's and other neurodegenerative conditions; and recombinant human Cerebral Dopamine Neurotrophic Factor (rhCDNF), a biological protein currently in Phase I clinical trials for patients with PD.
Show More
CEO
Antti Vuolanto
Employees
14
Country
Finland
ISIN
FI4000087861

Listings

HE
FI
HRTIS.HE

0 Comments

Share your thoughts

FAQs

What is Herantis Pharma OYJ stock price today?▼
The current price of HRTIS.HE is €1.19 EUR — it has increased by +0.51% in the past 24 hours. Watch Herantis Pharma OYJ stock price performance more closely on the chart.
What is Herantis Pharma OYJ stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Helsinki Exchange exchange Herantis Pharma OYJ stocks are traded under the ticker HRTIS.HE.
Is Herantis Pharma OYJ stock price growing?▼
HRTIS.HE stock has risen by +1.72% compared to the previous week, the month change is a -16.36% fall, over the last year Herantis Pharma OYJ has showed a -47.29% decrease.
What is Herantis Pharma OYJ market cap?▼
Today Herantis Pharma OYJ has the market capitalization of 31.43M
When is the next Herantis Pharma OYJ earnings date?▼
Herantis Pharma OYJ is going to release the next earnings report on March 4, 2027.
What were Herantis Pharma OYJ earnings last quarter?▼
HRTIS.HE earnings for the last quarter are -0.09 EUR per share, whereas the estimation was -0.06 EUR resulting in a -50% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Herantis Pharma OYJ revenue for the last year?▼
Herantis Pharma OYJ revenue for the last year amounts to 0 EUR.
What is Herantis Pharma OYJ net income for the last year?▼
HRTIS.HE net income for the last year is -6.62M EUR.
How many employees does Herantis Pharma OYJ have?▼
As of November 2, 2026, the company has 14 employees.
In which sector is Herantis Pharma OYJ located?▼
Herantis Pharma OYJ operates in the Health & Wellness sector.
When did Herantis Pharma OYJ complete a stock split?▼
Herantis Pharma OYJ has not had any recent stock splits.
Where is Herantis Pharma OYJ headquartered?▼
Herantis Pharma OYJ is headquartered in Espoo, Finland.